Fig. 2: Identifying and characterizing predicted PURE01 subtypes in the ABACUS cohort.

a The GLMnet classifier. Left: Heatmap of the 100 features used by the classifier, shown for the PURE01 pre-treatment cohort (n = 82) and its consensus subtypes. Right: Heatmap of the 100 classifier features in the ABACUS pre-treatment cohort (n = 84), with semi-supervised clustering within each of the predicted subtypes. The covariate track above the heatmap shows the predicted PURE01 subtype calls, while the covariate track below the heatmap shows the prediction probabilities for each subtype in each ABACUS sample. b GSEA results for selected MSigDB Hallmark gene sets for the five classifier-predicted subtypes in the ABACUS cohort. Enriched (vs. repressed) gene sets are shown as red (vs. blue) discs; disc areas are proportional to the areas-under-the-curve (AUCs) of the CERNO test results. c Kaplan–Meier plot for DFS for predicted subtypes in the ABACUS n = 84 pre-treatment cohort. d PD-L1(+) status in each PURE01 subtype and each classifier-predicted subtype in ABACUS. e Response (CR, PR, NR) for the classifier-predicted PURE01 subtypes in the ABACUS pre-treatment cohort. f Overall response (OR = CR + PR) for PURE01 subtypes and predicted subtypes in the ABACUS pre-treatment cohort. g Kaplan–Meier plot for DFS, in the atezolizumab arm of the IMvigor010 n = 670 MIBC cohort, for predicted subtypes S1 + S4 vs. predicted subtypes S2 + S3 + S5. The p-value is from a log-rank test, and is not corrected for multiple comparisons.